Jinzhong

Researchers are studying patients with unresectable non-small cell lung cancer (NSCLC) to evaluate the safety and effects of nintedanib combined with sequential radiotherapy. The study focuses on the incidence of radiation pneumonitis above grade 2 and also aims to explore progression-free survival (PFS) and overall survival (OS) in patients receiving this treatment alongside immunotherapy. This is a prospective, multicenter phase II clinical study. Patients first receive induction therapy, including chemotherapy and/or immunotherapy for at least one cycle. Following this, participants undergo sequential radiotherapy while taking nintedanib for six months. Afterward, they receive immunotherapy maintenance therapy for 16 cycles. Nintedanib is administered during the sequential radiotherapy period to observe its effects on radiation pneumonitis and safety. Throughout the study, patients will be closely monitored for safety and lung function changes. Researchers will assess the incidence rate of radiation pneumonia over up to two years and track progression-free and overall survival. The study requires patient cooperation for follow-up and compliance to assess the long-term outcomes and safety of combining nintedanib with radiotherapy and immunotherapy for unresectable NSCLC.

Researchers are studying the effects of normobaric oxygen (NBO) therapy on patients who have experienced an acute ischemic stroke (AIS) and are transferred for endovascular thrombectomy (EVT). The goal is to assess the safety and effectiveness of NBO in improving functional outcomes three months after stroke. Stroke is a major cause of death and disability worldwide, and while treatments like mechanical thrombectomy can improve blood flow, less than half of patients with large vessel occlusion achieve good recovery. NBO offers potential brain protection by improving oxygen delivery to affected areas and reducing damage through multiple mechanisms. Participants will receive either inhaled 100% oxygen (NBO) or best medical care without NBO. The study focuses on patients transferred for EVT who meet specific stroke severity and imaging criteria. NBO treatment is delivered through oxygen inhalation, aiming to increase oxygen availability to the brain before reperfusion. The study is conducted in a Phase 3 setting and compares outcomes between those receiving NBO and those receiving standard care. During the study, participants will be monitored for disability levels using the modified Rankin scale at 90 days and one year after treatment. Assessments include neurological exams and imaging to confirm stroke details and severity. Researchers will also track safety and functional outcomes to evaluate the impact of NBO therapy. Participants are followed for at least three months after randomization to observe recovery and potential benefits.

Researchers are evaluating the efficacy and safety of Shuxuening injection as an additional treatment to intravenous thrombolysis in patients with acute ischemic stroke. This multicenter, randomized, double-blind, placebo-controlled phase 3 trial involves patients aged 18 to 100 years who have experienced an ischemic stroke and can be treated within 6 hours of symptom onset. The study aims to improve functional outcomes by reducing brain cell death after stroke using this multi-target neuroprotective agent alongside the standard clot-busting therapy. Participants are randomly assigned in a 1:1 ratio to receive either Shuxuening injection or a placebo. Both groups receive a daily intravenous drip of 20 ml of the study drug or placebo combined with 250 ml of 0.9% sodium chloride injection for 10 to 14 days. The treatment starts as soon as possible after intravenous thrombolysis therapy, and the study compares these two groups to assess differences in recovery and safety. During the trial, researchers will monitor participants for 90 days after randomization. They will assess the primary outcome by measuring the proportion of patients achieving a modified Rankin Scale (mRS) score of 0 to 1, indicating good functional recovery. Safety will be evaluated by tracking adverse events over the same 90-day period. Participants will be closely followed with clinical evaluations to understand the effects and tolerability of Shuxuening injection in stroke recovery.

Researchers are investigating the prevalence, disease burden, and prognosis of chronic obstructive pulmonary disease (COPD) in patients aged 40 years or older with three types of cardiovascular diseases (CVD): coronary heart disease (CHD), atrial fibrillation (AF), and chronic heart failure (CHF). This multi-center, prospective, and interventional study aims to describe how common COPD is among these CVD patients and to observe how combined cardiopulmonary management affects their short-term prognosis. The study plans to enroll approximately 3,000 subjects, divided evenly among the three disease cohorts. The study involves a guideline education and implementation intervention delivered at both the investigator and patient levels. Investigators will receive education about COPD and CVD about four weeks before enrolling subjects. After enrollment, cardiologists and pulmonologists will provide patients with disease education every four weeks and collaborate on treatment management. Participants will be followed up every four weeks throughout the study period to monitor their health and treatment progress. Participants will undergo assessments including spirometry testing and questionnaires evaluated by investigators to confirm cognitive ability. Researchers will measure the number and percentage of COPD cases among subjects with CVD at baseline. Follow-up visits every four weeks will support ongoing treatment management and monitoring. The study duration and detailed timelines align with the intervention and follow-up schedules, ensuring comprehensive observation of patient outcomes and safety.

Researchers are evaluating the preliminary effectiveness and safety of Tislelizumab combined with thoracic radiotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer. This is a single-arm, open-label, multicenter phase II study focused on this specific lung cancer type. The study aims to measure progression-free survival over a period of up to two years. Participants receive Tislelizumab infusions at a dose of 200 mg every three weeks for up to two years. Additionally, chemotherapy with Etoposide is given intravenously at 100 mg/m2 on days 1 to 3 every three weeks for four cycles. Patients also receive either Carboplatin or Cisplatin chemotherapy intravenously every three weeks for four cycles, with dosages adjusted accordingly. Concurrently, thoracic radiotherapy is administered using intensity-modulated radiation therapy (IMRT) at doses ranging from 30 to 45 Gy delivered in 10 to 15 fractions. Throughout the study, patients undergo regular imaging to evaluate measurable lesions and assessments to monitor vital organ function and overall health. The main outcome measured is progression-free survival for up to two years. Researchers also monitor safety and treatment compliance, and participants are followed closely to observe treatment effects and any side effects during and after the therapy period.